• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Report: Drug device market to reach $1.8B by 2024

October 5, 2016 By Sarah Faulkner

generic-drugs-money-1x1The global drug device combination market is expected to reach $17.7 billion by 2024, according to a new report from Grand View Research.

The report points to minimally invasive alternatives like transdermal patches as high-impact growth drivers in the industry.

As researchers develop these products, regulatory agencies have taken notice and the report notes that there is an increasing regulatory presence enforcing defined protocols for premarket authorizations.

This will support manufacturers in the development and approval process, authors write. Specifically, the report cites the FDA’s lean management approach to streamline and systematically review products.

North America has the largest drug device combination regional market, with a 42% share in 2015. “Rising chronic disease burden in this region is believed to be one of the key potential growth factors responsible for the high clinical urgency to incorporate these products,” according to the report.

The Asia Pacific region is expected to grow, with increasing healthcare spending and a heightened awareness among physicians that particular drug device combination products could help their patients.

Technological innovations, such as programmable external devices and microdose infusions, are driving growth in the industry. The report anticipates that patients will continue to prefer self-administration techniques that keep them from costly visits to the hospital. Inhalers are expected to grow profitably over the forecast period, especially as COPD and asthma incidences continue to rise. The Internet of Things will play an important role in product development, as manufacturers move to make connected devices.

Key players in the industry include Medtronic (NYSE: MDT) and Boston Scientific (NYSE: BSX), according to the report. Extensive expansion strategies, innovative product development, and M&A were some of the vital characteristics that the report highlighted.

Grand View Research pointed to Medtronic’s MiniMed 630G insulin pump that it launched in the US in August 2016 as an example, since the product serves a large patient population with chronic needs.

Filed Under: Business/Financial News, Drug-Device Combinations, Featured Tagged With: Boston Scientific, Medtronic

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS